PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424358
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424358
The global artificial intelligence in oncology market size is expected to reach US$ 9,164.2 Mn by 2030, from US$ 1,200 Mn in 2023, at a CAGR of 33.7% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 1,200 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 33.70% | 2030/2031 Value Projection: | US$ 9,164.2 Mn |
Artificial intelligence (AI) plays an important role in oncology. There are various types of AI products that are helping in cancer screening, diagnosis, treatment, and drug development. One of the major products is an AI-assisted cancer screening tool. These tools use deep learning algorithms that have been trained on huge databases of medical images. They help physicians detect abnormalities in scans like CT, MRI, or mammograms. They can rapidly analyze a large number of images and highlight suspect areas that the doctor may miss with human screening alone. This improves the accuracy of detecting tumors at early stages and increases the number of lives saved. However, the algorithms need continuous updates with new data to improve over time. Misdiagnosis is also a risk because the AI may not be able to distinguish rare cancer types effectively.
Other important applications include the use of AI in cancer diagnostics, prognosis, and therapeutics. Using machine learning on vast pools of genomic and clinical cancer datasets, AI can recognize complex patterns, emerge with new insights, and predict treatment responses better than humans. This helps with customized and targeted therapy. AI is also speeding up drug development by assisting in target identification, compound screening, and clinical trial optimization.
Rising cancer incidence coupled with the increasing complexity of cancer treatment decisions is a key factor driving the adoption of AI solutions in oncology. The growing availability of digital health data and computational power is facilitating the development of advanced AI technologies. However, the high investment and costs required for the development of precision and clinical-grade AI solutions are a major restraint. Lack of interpretability and understanding of how AI arrives at its decisions also limits widespread adoption. Meanwhile, the potential of AI to help overcome drug resistance by enabling personalized treatment selection presents an opportunity. Partnerships between technology companies and research institutes aim to further validate the clinical applicability of AI.
Among regions, North America dominates the market due to high healthcare expenditures and better access to care. However, Asia Pacific is poised to be the fastest-growing market arena, led by countries like China and India. This growth can be attributed to growing economies, rising disposable incomes, expanding medical infrastructure, and the increasing adoption of technologically advanced cancer diagnostic tools.
Global Artificial Intelligence in Oncology Market Segmentation: